<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03089073</url>
  </required_header>
  <id_info>
    <org_study_id>000208</org_study_id>
    <nct_id>NCT03089073</nct_id>
  </id_info>
  <brief_title>Study of Minirin Melt® in Adult Patients With Nocturia</brief_title>
  <official_title>Non-interventional Study on Safety and Efficacy of Minirin Melt® in Adult Patients With Nocturia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ferring Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ferring Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Observation of safety and efficacy of Minirin Melt® in adult patients with nocturia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 13, 2015</start_date>
  <completion_date type="Actual">October 5, 2018</completion_date>
  <primary_completion_date type="Actual">October 5, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean number of nocturnal voids</measure>
    <time_frame>Baseline and treatment-related visits up to 3 months</time_frame>
    <description>Calculated by 72 hour frequency volume chart (FVC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reduction from baseline in the mean number of nocturnal voids</measure>
    <time_frame>Baseline and treatment-related visits up to 3 months</time_frame>
    <description>Assessed as a (50% decrease) or reduction of nocturnal diuresis (&gt;20%)</description>
  </secondary_outcome>
  <enrollment type="Actual">835</enrollment>
  <condition>Nocturia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desmopressin</intervention_name>
    <description>60μg or 120μg once daily at bedtime</description>
    <other_name>Minirin Melt®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Only patients to whom Minirin melt is prescribed as regular treatment is included in
        accordance with their usual practice and consistent with Korean prescribing information for
        Minirin melt.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult aged between 19 and 65 years

          -  Patients having nocturia

          -  Decision made to prescribe Minirin Melt according to prescription information

          -  Willingness and ability to provide written informed consent

        Exclusion Criteria:

          -  When patients have habitual or psychogenic polydipsia (resulting in a urine production
             exceeding 40ml/kg/24hours)

          -  When patients have a history of known or suspected cardiac insufficiency and other
             conditions requiring treatment with diuresis

          -  When patients have moderate and severe renal insufficiency (creatinine clearance below
             50ml/min)

          -  When patients have known hyponatremia

          -  When patients have secretion Syndrome of Inappropriate Antidiuretic Hormone Secretion
             (SIADH)

          -  When patients have hypersensitivity to the active substances or to any of the
             excipients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Compliance</last_name>
    <role>Study Director</role>
    <affiliation>Ferring Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Daegu Fatima Hospital (there may be other sites in this country)</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>February 6, 2020</last_update_submitted>
  <last_update_submitted_qc>February 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nocturia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deamino Arginine Vasopressin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

